iiinova — where your digital self keeps evolving

Reposted by Post-Viral Trials

C.H. Romatowski @chromatowski.bsky.social · 25/09/2026

New RCT of a valacyclovir, celecoxib, and nirmatrelvir/ritonavir combo for Long Covid starting at Mount Sinai. Phase 2, enrolling 150 people. Builds on this open-label case series: www.frontiersin.org/journals/imm...

markets.businessinsider.com

PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment

TUSCALOOSA, Ala., Sept. 24, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics, LLC, a clinical-stage biopharmaceutical company developing combinatio...

1227

Reposted by Post-Viral Trials

Long COVID Labs @longcovidlabs.bsky.social · 25/09/2026

🚨Important: Dr. Nancy Klimas’ sipavibart trial needs to enroll 5 more Long COVID participants by of this month! Details: 👇 www.reddit.com/r/covidlongh...

reddit.com

From the covidlonghaulers community on Reddit: Sipavibart trial run by Nancy Klimas needs 5 more Long COVID enrollees by the end of the month

Posted by LRay_007 - 95 votes and 30 comments

034

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 20/09/2026

5) The primary outcome was the Brief Pain Inventory-Short Form (BPI-SF), which measures not only pain but also the impact on various activities and aspects of life. The treatment group improved by 0.5 out of range of 10 points, which wasn't statistically significant.

181

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 20/09/2026

1) The team of Andreas Goebel was the first to transfer autoantibodies of fibromyalgia patients to mice (similar studies later followed in Long Covid). In this paper, they tested rozanolixizumas: a drug that lowers circulating antibody levels. A brief summary of the results 👇

2189

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 17/09/2026

1) The pharma company BioVie announced the results of the phase 2 trial of their drug Bezisterim for Long Covid. Although the primary analysis showed no significant effect, an analysis in subgroups with a great symptom burden suggested an improvement. A brief breakdown 👇

1238

Reposted by Post-Viral Trials

It's ME(Jaime) @exceedhergrasp1.bsky.social · 11/09/2026

Now they're initiating trials using anti-CD38 and anti-CD14 antibodies, with some promising results. This one was unfortunately quite a lot, referenced a large number of publications-- sorry I could not hunt them down fast enough! Remember the recording will be out there in a week or so, likely.

1122

Reposted by Post-Viral Trials

It's ME(Jaime) @exceedhergrasp1.bsky.social · 11/09/2026

Rob is hoping to present results on this trial next year:

Sonlicromanol phase 2 trial

- A flow diagram shows Long COVID leading to an “Unknown X-factor,” which is proposed to cause mitochondrial dysfunction
- Mitochondrial myopathies are also shown as a route to mitochondrial dysfunction
- The dysfunctional mitochondrion is illustrated in pink with a damaged, irregular outer edge
- Mitochondrial dysfunction is linked to:
- Fatigue
- Worsening after exercise / PEM
- Orthostatic intolerance
- An arrow labeled “sonlicromanol” leads from the damaged pink mitochondrion to a healthy-looking green and blue mitochondrion
- The treated or restored mitochondrion is linked to:
- Improved exercise capacity
- Less fatigue
- Higher PEM threshold
- Shorter PEM duration
- Improved quality of life

Image description: The slide uses contrasting illustrations of a damaged pink mitochondrion and a healthy green-and-blue mitochondrion to depict the proposed effect of sonlicromanol. Khondrion and Amsterdam UMC logos appear at the bottom.

1162

Post-Viral Trials @postviraltrials.bsky.social · 04/09/2026

“It is no longer the science, Dr. Hong believes, that is holding back potential cures, but our capacity to try new medicines in clinical trials.” www.nytimes.com/2026/09/04/o...

nytimes.com

Opinion | The Search for New Cures Is Broken (Gift Article)

It is too hard for medical researchers to launch clinical trials.

022

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 31/08/2026

1) Very sad news that Jo Cambridge has passed away. She was a Prof. in rheumatology who pioneered B-cell depletion therapy in autoimmune diseases together with Jonathan Edwards. But she also did several useful studies on ME/CFS and was much loved in the community.

13812

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 13/08/2026

1) Unfortunately, another negative result for immunoadsorption for Long Covid. A small trial that focused only on patients with elevated levels of antibodies against β1/β2-adrenergic and/or M3/M4-muscarinic acetylcholine receptors found no improvement in objective outcomes.

1247

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 27/07/2026

3) The trial also focuses on a very specific subset of ME/CFS patients with elevated antibodies against β2-adrenergic receptors and "a pro-inflammatory immune cell status."

181

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 27/07/2026

2) Inebilizumab targets the CD19 a marker on B-cells; the immune cells that produce antibodies. Compared to Rituximab (which targets CD20), inebilizumab targets a broader range of B-cell subsets, including early B cells and plasmablasts.

182

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 27/07/2026

1) 🇩🇪 There's now more info about the PIONEER study which will test inebilizumab (a drug that targets B-cells), in a subgroup of ME/CFS patients. It's a randomised trial at the Charité that aims to include 38 participants.

Screenshot of the trial registration for the PIONEER trial on inebilizumab

13310

Reposted by Post-Viral Trials

Jon Douglas @atranscendedman.bsky.social · 28/07/2026

Vrije Universiteit Amsterdam, 105 participants. Long COVID and ME/CFS muscles had impaired mitochondrial energy production and fewer capillaries for their size, unlike 60 days of bed rest. Inactivity alone did not explain this. www.nature.com/articles/s41...

nature.com

Skeletal muscle properties in long COVID and ME/CFS differ from those induced by bed rest - Nature Communications

Low aerobic capacity in patients with long COVID and ME/CFS is often attributed to physical inactivity. The authors show that long COVID and ME/CFS patients have distinct skeletal muscle changes that ...

01611

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 18/07/2026

2) The treatment trial is led by Carmen Scheibenbogen and will be a follow-up study to the randomized Phase II trial of the CD19 antibody inebilizumab. Tafasitamab also targets CD19 but is less expensive, so they want to test if this also works in a subgroup of 38 patients.

1112

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 18/07/2026

1) 🇩🇪 The German ME/CFS Research Foundation has supported 7 research projects with a total budget of € 2.4 million. It includes a treatment trial of tafasitamab, which targets B-cells, and a genetic study of families with multiple members affected by ME/CFS A brief overview

24110

Reposted by Post-Viral Trials

Solve M.E. @solveme.bsky.social · 13/07/2026

If you were a participant in the Vyvgart trial, please email Mackenzie at coreresearch@mountsinai.org to get a free at-home lab kit. Mt. Sinai & Yale are testing against a newly discovered autoimmune biomarker, with the goal of initiating a new FCRN inhibitor trial by year-end!

Notice for 2023-2024 long COVID trial participants to donate blood for autoimmune biomarker research at Mt. Sinai.

01719

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 13/07/2026

1) 🇮🇹 An Italian hospital showed reduced nerves in the gastric lining of Long Covid patients compared to controls. It was a preliminary study though, with only 12 patients and 8 controls.

Figure1. Gastric mucosa denervation in Long-COVID-19 patients. The panel shows
gastric mucosa denervation in Long-COVID-19 patients in the fundus in A and C and compared to controls.

1196

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 11/07/2026

9) Link to the paper: Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial www.thelancet.com/jo...

061

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 11/07/2026

2) The graph below shows the main findings. Unfortunately, there wasn't a placebo control group only a group that received no drug, only usual care. The primary outcome was the Fatigue Assessment Scale (FAS, range: 10-50), with higher scores indicating worse fatigue.

161

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 11/07/2026

1) 🇬🇧 The results of the big STIMULATE-ICP study are in. It tested three repurposed drugs in hundreds of Long Covid patients: - colchicine: an anti-inflammatory - famotidine and loratadine: antihistamines - rivaroxaban: an anticoagulant Sadly, all three had poor results.

1247

Reposted by Post-Viral Trials

Ezra S @ezra.zone · 10/07/2026

By itself, administered subcutaneously. clinicaltrials.gov/study/NCT071...

clinicaltrials.gov

ClinicalTrials.gov

031

Reposted by Post-Viral Trials

Ezra S @ezra.zone · 10/07/2026

Anktiva at UCSF

181

Reposted by Post-Viral Trials

Ezra S @ezra.zone · 10/07/2026

well, it happened: i have now taken cancer drugs (as part of a clinical trial) to see what they do for my long covid.

10647

Reposted by Post-Viral Trials

Jon Douglas @atranscendedman.bsky.social · 07/07/2026

Geneva University Hospitals, 203 people. Temelimab targeted HERV-W ENV, a proposed immune trigger in Long COVID, but did not improve fatigue, cognition, function, or biomarkers versus placebo after 24 weeks. www.sciencedirect.com/science/arti...

sciencedirect.com

Temelimab versus placebo in patients with post-COVID condition

More than 400 million individuals are estimated to have been affected by post-COVID condition or long COVID. This condition can lead to significantly …

033

Post-Viral Trials @postviraltrials.bsky.social · 08/07/2026

Oh no, I spent forever waiting for the video of Dr. Fluge’s daratumumab trial update at the International ME/CFS Conference 2026 to be uploaded, and now it looks like it won’t be at all. Bummer, I was really looking forward to watching that! events.mecfs-research.org/en/events/co...

events.mecfs-research.org

ME/CFS Research Foundation

280

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 04/07/2026

1) 🇬🇧 The ME Association is recruiting patients for a study that will test oxygenation and energy recovery in the calf muscles of ME/CFS patients. The study will use non-invasive technologies such as magnetic resonance imaging (MRI) and near-infrared spectroscopy (NIRS).

2269

Reposted by Post-Viral Trials

Tom Kindlon @tomkindlon.bsky.social · 02/07/2026

New from Spain: Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled...trial onlinelibrary.wiley.com/doi/10.1002/... #LDN #Fibromyalgia #ChronicPain

184

Reposted by Post-Viral Trials

Tom Kindlon @tomkindlon.bsky.social · 19/06/2026

Transcutaneous Auricular Vagus Nerve Stimulation for Post-COVID-19 Condition: A Systematic Review and Critical Appraisal of Clinical Evidence www.mdpi.com/2077-0383/15... Screenshot from latest Science for ME weekly update #LongCovid #PASC

0143

Reposted by Post-Viral Trials

Science for ME (S4ME) @s4me.info · 08/06/2026

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial — Bramante et al "Metformin did not exceed the primary outcome threshold for declaring efficacy for reducing PASC." #MECFS

dx.doi.org

Article Link

021

Reposted by Post-Viral Trials

VirusSucks.com @virussucks.com · 26/05/2026

Did you participate in this Vyvgart clinical trial for #LomgCOVID? If so, Mt. Sinai needs your blood to analyze a potential autoimmune biomarker that might help millions.

1913

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 30/05/2026

18) Overall, this is an impressive, in-depth paper providing evidence for autoimmunity in a subset of LC patients. But a decisive result of identifying a specific antibody that is pathological and causes symptoms, wasn’t achieved (yet).

3122

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 30/05/2026

12) On the hot plate test, the mice that received LC antibodies were faster to withdraw their paws indicating increased pain sensitivity (Figure 6C)

161

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 30/05/2026

10) The strongest results in the paper are the transfer of antibodies to mice who then developed symptoms such as pain sensitivity. Similar findings have been reported by the groups of Jeroen Den Dunnen, Charles Nicaise and Andreas Goebel.

1102

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 30/05/2026

8) One of the top hits was antibodies against the Mediator Complex Subunit 20 (MED20) which is involved in turning genes on and off. The paper lists findings suggesting these antibodies are pathologic such as reduced IgM/IgG ratio, complement deposition, etc.

171

Reposted by Post-Viral Trials

ME/CFS Science @mecfsscience.org · 30/05/2026

1) Impressive paper from Iwasaki’s lab pointing at autoimmunity in a subgroup of Long Covid patients. They replicated previous experiments of antibody transfer causing symptoms in mice. A couple of findings that stand out…

14915

Reposted by Post-Viral Trials

BioVie Inc @biovie.bsky.social · 26/05/2026

Enrollment is complete in our Phase 2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected in late summer 2026. Learn more: investors.bioviepharma.com/news/news-de...

LONG COVID UPDATE
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

1115

Reposted by Post-Viral Trials

Daniel Missailidis, PhD @danielmissailidis.bsky.social · 26/03/2026

Advert documents attached as images!

098